A Novel Function of Artesunate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Rheumatoid Arthritis Patients
Overview
Authors
Affiliations
Introduction: Anti-malarial drug artesunate can suppress inflammation and prevent cartilage and bone destruction in collagen-induced arthritis model in rats-suggesting it may be a potent drug for rheumatoid arthritis (RA) therapy. We aimed to investigate its effect on the invasive property of fibroblast-like synoviocytes (FLS) from patients with RA.
Methods: Synovial tissues were obtained by closed needle biopsy from active RA patients, and FLS were isolated and cultured in vitro. RA-FLS were treated with artesunate at various concentrations, while methotrexate or hydroxychloroquine was employed as comparator drugs. Cell viability, proliferation, cell cycle, apoptosis, migration, invasion, and pseudopodium formation of RA-FLS were assessed by CCK-8 assays, EdU staining, Annexin V-FITC/PI staining, transwell assays, or F-actin staining, respectively. Further, relative changes of expressed proteases were analyzed by Proteome profiler human protease array and verified by quantitative real-time PCR (qPCR), Western blot, and ELISA. The expression of signaling molecules of MAPK, NF-κB, AP-1, and PI3K/Akt pathways were measured by qPCR and Western blot. PDK-1 knockdown by specific inhibitor AR-12 or siRNA transfection was used to verify the pharmacological mechanism of artesunate on RA-FLS.
Results: Artesunate significantly inhibited the migration and invasion of RA-FLS in a dose-dependent manner with or without TNF-α stimulation. The effect was mediated through artesunate inhibition of MMP-2 and MMP-9 production, and pre-treatment with exogenous MMP-9 reversed the inhibitory effect of artesunate on RA-FLS invasion. Artesunate had a stronger inhibitory effect on migration and invasion of RA-FLS as well as greater anti-inflammatory effect than those of hydroxychloroquine. Similar inhibitory effect was detected between artesunate and methotrexate, and synergy was observed when combined. Mechanistically, artesunate significantly inhibited PDK-1 expression as well as Akt and RSK2 phosphorylation-in a similar manner to PDK-1-specific inhibitor AR-12 or PDK-1 knockdown by siRNA transfection. This inhibition results in suppression of RA-FLS migration and invasion as well as decreased MMP-2 and MMP-9 expression.
Conclusions: Our study demonstrates artesunate is capable of inhibiting migration and invasion of RA-FLS through suppression of PDK1-induced activation of Akt and RSK2 phosphorylation-suggesting that artesunate may be a potential disease-modifying anti-rheumatic drug for RA.
Wu H, Yin F, Wang Y, Tang Z, Hong H, Jiang T Clin Rheumatol. 2025; .
PMID: 39953337 DOI: 10.1007/s10067-025-07361-8.
Hu S, Batool Z, Zheng X, Yang Y, Ullah A, Shen B J Pharm Anal. 2025; 15(1):101084.
PMID: 39896318 PMC: 11786068. DOI: 10.1016/j.jpha.2024.101084.
Long Z, Xiang W, Xiao W, Min Y, Qu F, Zhang B Front Immunol. 2024; 15:1432625.
PMID: 39524446 PMC: 11543433. DOI: 10.3389/fimmu.2024.1432625.
Zheng J, Xiong X, Li K, Wang G, Cao H, Huang H J Inflamm Res. 2024; 17:7221-7234.
PMID: 39416266 PMC: 11479950. DOI: 10.2147/JIR.S476077.
Tang Q, Wang J, Zhang J, Zeng H, Su Z, Zhu X Mikrochim Acta. 2024; 191(11):665.
PMID: 39397178 DOI: 10.1007/s00604-024-06707-4.